Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H11N5O |
Molecular Weight | 241.2486 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(NC=C2CC3=CN=CC=C3)C(=O)N1
InChI
InChIKey=DOHVAKFYAHLCJP-UHFFFAOYSA-N
InChI=1S/C12H11N5O/c13-12-16-9-8(4-7-2-1-3-14-5-7)6-15-10(9)11(18)17-12/h1-3,5-6,15H,4H2,(H3,13,16,17,18)
Peldesine (also known as BCX-34) was developed as a purine nucleoside phosphorylase (PNP) inhibitor. It is known PNP inhibitors may be useful for treating a variety of T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis, and Crohn s disease and T-cell cancers. Peldesine has undergone phase I trials for the treatment of human Immunodeficiency virus (HIV) infections. In addition, this drug participated in phase III clinical trial as a topical therapy for cutaneous T-cell lymphoma. This drug was also studied as a potential therapy for psoriasis, multiple sclerosis; rheumatoid arthritis; transplant rejection. However, all these indications were discontinued because of the lack of significant effects over placebo.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. | 2001 Jun |
|
Biological activity of inorganic arsenic and antimony reflects oxidation state in cultured human keratinocytes. | 2003 Dec |
|
Case study: institutional review board (IRB) did not know about subject problem until after study. | 2006 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11369904
peldesine (BCX-34) in a 1% dermal cream formulation. BCX-34 dermal cream 1% or the vehicle cream (as a placebo control) was applied twice daily to the entire skin surface for up to 24 weeks.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2151
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
||
|
FDA ORPHAN DRUG |
76293
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7405
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
GG-27
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
DTXSID10158107
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL311300
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
C1650
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
135413525
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
133432-71-0
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
C104194
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
DB02568
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
7B646RJ70F
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
SUB09649MIG
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY | |||
|
100000083007
Created by
admin on Sat Dec 16 06:14:35 GMT 2023 , Edited by admin on Sat Dec 16 06:14:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY